AWC
NBIX icon

Abundance Wealth Counselors’s Neurocrine Biosciences NBIX Stock Holding History

Abundance Wealth Counselors’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$241K Sell
1,429
-499
-26% -$74K 0.02% 265
2026
Q1 		$254K Buy
+1,928
New +$256K 0.04% 202

Other funds holding NBIX

Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
Handelsbanken Fonder
Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return
PBBUPS
PKO BP Bankowy Universal Pension Society Warsaw, Poland $350M AUM 272.18% 1-Year Est. Return
Robeco Institutional Asset Management
Robeco Institutional Asset Management Rotterdam, Netherlands $81.4B AUM 40.71% 1-Year Est. Return
New York State Teachers Retirement System (NYSTRS)
New York State Teachers Retirement System (NYSTRS) Albany, New York $54.2B AUM 43.77% 1-Year Est. Return
CAM
Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return
HP
HealthInvest Partners Stockholm, Sweden $372M AUM 59.89% 1-Year Est. Return
Wealth Enhancement Advisory Services
Wealth Enhancement Advisory Services Plymouth, Minnesota $59.8B AUM 29.42% 1-Year Est. Return
AB
Amalgamated Bank New York $14.5B AUM 44.3% 1-Year Est. Return

Abundance Wealth Counselors's NBIX Position: Q2 2026 in Review

Abundance Wealth Counselors reduced its Neurocrine Biosciences (NBIX) stake by 26% in Q2 2026, selling an estimated $74K and leaving 1,429 shares worth $241K. The position accounts for 0.02% of the portfolio, ranked #265.

Abundance Wealth Counselors first reported a position in NBIX in Q1 2026 and has held it in 2 quarters since. The position peaked at $254K in Q1 2026. 166 funds tracked by Wall St. Rank hold NBIX as of Q2 2026.

  • Abundance Wealth Counselors held 1,429 shares of Neurocrine Biosciences worth $241K as of Q2 2026.
  • Abundance Wealth Counselors sold 499 Neurocrine Biosciences shares in Q2 2026, an estimated $74K.
  • Neurocrine Biosciences made up 0.02% of Abundance Wealth Counselors's portfolio in Q2 2026, its #265 holding.
  • Abundance Wealth Counselors first reported a position in Neurocrine Biosciences in Q1 2026 and has held it in 2 quarters since.
  • Abundance Wealth Counselors's Neurocrine Biosciences position peaked at $254K in Q1 2026.
  • 166 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2026.

Based on Abundance Wealth Counselors's 13F filing for Q2 2026, filed 23 Jul 2026.